静脉注射免疫球蛋白治疗肌炎：南澳大利亚患者的审计。

Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.

机构信息

Immunology Department, SA Pathology Flinders Medical Centre, Adelaide, South Australia, Australia.

Immunology Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

出版信息

Intern Med J. 2017 Jan;47(1):112-115. doi: 10.1111/imj.13308.

DOI:10.1111/imj.13308

PMID:28076913

Abstract

In South Australia, between 2000 and 2014, 57 patients with idiopathic inflammatory myositis (IIM) were treated with intravenous immunoglobulin (IVIg). We reviewed disease characteristics to determine predictors of response to therapy and IVIg dosing and duration to identify opportunities to rationalise IVIg use. Patients with dermatomyositis/polymyositis had a response rate of 77% and were more likely than inclusion body myositis to respond to therapy. Consideration should be given to the use of the lowest possible dose of IVIg and to the undertaking of trials of cessation of IVIg in patients with stable IIM.

摘要

在 2000 年至 2014 年期间，南澳大利亚有 57 名特发性炎性肌病（IIM）患者接受了静脉注射免疫球蛋白（IVIg）治疗。我们回顾了疾病特征，以确定对治疗和 IVIg 剂量和持续时间的反应的预测因素，以确定合理使用 IVIg 的机会。皮肌炎/多发性肌炎患者的反应率为 77%，比包涵体肌炎更有可能对治疗有反应。应考虑使用尽可能低剂量的 IVIg，并在稳定的 IIM 患者中进行停止 IVIg 的试验。